| Active substance | tralokinumab |
| Holder | LEO Pharma |
| Status | closed |
| Indication | Adolescent patients (12 ≤ 18 years) with severe atopic dermatitis (and a body weight < 60 kg) who are candidate for systemic treatment (including patients from the open label extension study ECZTEND LP0162-1337) |
| Public documents | Approbation |
| Approbation amendment | |
| Information for the patient | |
| Informed consent | |
| Laste update | 26/10/2023 |